Receive Dave's best setups each evening from his favorite trading patterns.
Categories
- Music Bands
- Music Stars
- Music Styles
- Blues
- Country Music
- Pop Music
- Hip Hop
- Rock
- Rap
- Christian Music
- House Music
- African Music
- Opera
- Electronic Music
- Disco
- Folk
- Progressive Rock
- Celtic Music
- Middle Eastern Music
- Rhythm and Blues
- Traditional Pop
- Big Band
- Dance
- Experimental Music
- Heavy Metal
- Latin Music
- Punk
- Jazz
- Alternative Rock
- Religious Music
- Classical Music
- Reggae
- Swing
- Techno
- Vocal
- Music Performances
- Soundtrack Styles
Popular news
- TIA Forecasts Double-Digit Handset Volume Growth - 2/26/2007 - TWICE
Amber SwiftARLINGTON, VA. Last year was the last year for double-digit percentage growth in the U.S...
- Nokia Intros Fully-Loaded Music Phone
Travis RoySave on a great selection of Desktop PCs at the official HP Home Home Office Store. Find HP Pavilion desktop PCs, Photosmart PCs, Compaq Presario Desktop PCs, HP Digital Entertainment Centers and more. Shop now...
- Squarefootball diary; Lamps And Co Lamp Villa; Blues Agger-ny; Gers Jolted By St.Johnstone
Dwayne JenkingsSomebody had to give Aston Villa a good old larruping at some stage, and who better than those moneybags enemies of football Chelsea? Jose Mourinho...
- Lost-In-Tyme: Ale Möller Band - Bodjal (2004)
Ram StoneAle Möller comes full circle. From the bouzoukispellman who learned Swedish folk music on a Greek instrument so many years ago comes a stunning new album of music that starts with those Greek roots, and then explodes across the continents...
- capsule movie reviews
Dwayne JenkingsDec. 21, 2006) reviewed by the Office for Film Broadcasting of the U.S. Conference of Catholic Bishops. Charming live-action adaptation of E.B...
- Here are the week's best releases from the pop-culture universe:
Justin Henine-HardenneCD -- U218 Singles : After more than a quarter-century, the world's biggest band finally releases its first single-disc best-of set...
- African Bullets Honey: Mass of Appetites: A Nairobi Bar Horror Story II
Dwayne JenkingsThe Mass of Appetites is always on the make, out on the town most nights of the week, like a shark that cannot stop swimming and hunting for a single moment lest it drown...
Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 486146
Let Gary Kaltbaum send you timely emails to alrt when breakouts occure.
Every day receive the best plan of attack for the next day's trading directly from professional trader Kevin Haggerty.| Sam Boyle | by www.tradingmarkets.com. All rights reserved. | 10.11 | 17:09 |
( | | | ) reported a wider loss in the third quarter. The company recorded no revenues in the quarter. The company posted third quarter net loss of $3.
82 million or $0.15 per share, compared to net loss of $1.74 million or $0.
07 per share in the same quarter last year. The current year quarter loss from continuing operations widened to $3.75 million or $0.
15 per share from $1.76 million or $0.07 per share in the previous year.
A.P. Pharma reported no revenues in the third quarter, which reflected the sale effective October 1, 2005, of rights to receive royalties on sales of Retin-A Micro and Carac.
In the same quarter of the prior year, the company recorded royalty revenues of $1.3 million related with sales of the above products. Total operating expenses for the quarter increased to $3.
95 million from $3.17 million in the previous year. The company's third quarter operating loss widened to $3.
95 million from $1.84 million in the previous year. For the third quarter, research and development expense totaled $3.
1 million, up 35% compared to $2.3 million in last year's third quarter. The company said the increase reflected the higher cost levels related with its Phase 3 study for APF530 compared to those incurred for its Phase 2 study last year.
For the nine-month period, the company reported a profit of $10.93 million or $0.43 per share, compared to a loss of $5.
61 million or $0.22 per share in the comparable period last year. For the period, income from continuing operations was $11.
02 million or $0.43 per share, compared to a loss of $5.58 million or $0.
22 per share in the year earlier. The company recorded no revenues for the current year six-month period, compared to revenues of $3.95 million in the previous year same period.
The company said that it is continuing to gain additional opportunities for partnering the development of APF530 prior to completion of the Phase 3 trials. APF530, which contains the 5HT3 antagonist anti-nausea drug granisetron is formulated with the company's proprietary Biochronomer bioerodible drug delivery system. This is being developed for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing either moderately or highly emetogenic chemotherapy for cancer.
The company said that it expect to provide initial data from its Phase 3 clinical trial with APF530 in the second half of 2007. The company revised the time due to slower-than-expected start in getting IRB approvals and clinical sites prepared to begin enrolling patients, and in recruiting patients during the summer months. APPA closed Monday's regular trading session at $1.
10, up $0.04, on a volume of 221K shares.
News RSS